In Brief: Lipoplasty device downclassification
This article was originally published in The Gray Sheet
Final rule downclassifying suction lipoplasty systems for use in aesthetic body contouring from Class III to Class II published in the Feb. 17 Federal Register. The reclassification becomes effective March 19. FDA announced its intention to downclassify suction lipoplasty systems in November 1996 ("The Gray Sheet" Nov. 18, 1996, I&W-2). The agency issued the downclassification proposal based on findings in support of a 1989 recommendation by FDA's General and Plastic Surgery Devices Panel to downclassify the devices. The American Society for Aesthetic Plastic Surgery filed a petition in December 1988 requesting the downclassification...
You may also be interested in...
Interview: recently appointed CEO Richard Francis will apply his background in big pharma and biotech to building the UK start-up Purespring Therapeutics with a focus on using gene therapy technology to target renal diseases.
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.